|
Press Contacts
John Lacey
Associate Director, Corporate Communications
Phone: 617-768-6690
Corporate/executive issues; Financial results; Massachusetts issues; Public policy; Oncology (Campath, Clolar) and Alemtuzumab for MS.
|
Lori Gorski
Associate Director, Corporate Communications
Phone: 617-768-9344
Genetic diseases (Cerezyme, Fabrazyme, Aldurazyme, Myozyme); Transplant (Thymoglobulin, Mozobil); Biosurgery (Synvisc) and Corporate Social Responsibility.
|
Erin Emlock
Associate Manager, Corporate Communications
Phone: 617-768-6923
Renal disease (Renagel, Renvela, Hectorol); Endocrinology (Thyrogen); Cardiovascular disease (mipomersen); Diagnostics (point-of-care testing); Gene therapy; HR topics; Facilities and Environmental initiatives.
|
Sarah Millerick
Senior Corporate Communications Specialist
Phone: 617-768-6438
Genetics (reproductive and cancer testing); Cell therapies (Carticel and Epicel); Biosurgery (Seprafilm); and Community Relations.
|
Heidi De Wit
Director, Corporate Affairs Europe
International Issues
Phone: +32 2 714 17 42
|
Caroline De Bie
Corporate Communication Manager, Europe
European Issues
Phone: +32 2 714 17 45
|
If you would prefer to send an email please contact Media Relations.
If you are not a journalist and are calling with a general question about Genzyme, please call our main phone number:
617-252-7500.
|
Home
